From the Department of Family and Community Medicine, Wake Forest School of Medicine, Winston-Salem, NC (AYS, JKK, BJW); Department of Information Technology Services, Wake Forest School of Medicine, Winston-Salem, NC (PFS); Division of Public Health Sciences, Department of Biostatistical Sciences, Center for Biomedical Informatics, Winston-Salem, NC (BJW).
J Am Board Fam Med. 2021 Jan-Feb;34(1):99-104. doi: 10.3122/jabfm.2021.01.200320.
Higher daily doses of opioids as well as co-prescription of benzodiazepines have been associated with risk of overdose. The current study characterizes prescribing patterns in a family medicine practice with regard to patient mental health diagnoses, benzodiazepine prescriptions, morphine milligram equivalent opioid dose, and patient demographics.
Patients on chronic opioid therapy were studied in 2018 and 2019. Mental health diagnoses, opioid dose, benzodiazepine prescriptions and demographic characteristics were extracted from the electronic health record. Data were compared between years and logistic regression was used to determine which patient characteristics were associated with likelihood of decreased opioid dose.
A total of 387 patients were prescribed chronic opioid therapy in 2018, and 231 in 2019. In 2018, 49.9% of patients prescribed chronic opioids had mental health diagnoses. In 2019, this proportion rose to 92.2%. In 2019, 205 of the original 387 patients were still with the practice but were not prescribed chronic opioids. Among the factors studied, psychiatric diagnosis and higher opioid dose were associated with a significantly lower likelihood of tapering doses.
As practices taper or de-prescribe opioids, or implement harm reduction methods such as de-prescribing benzodiazepines, it is important to understand patient characteristics and their relationship to success with tapering. This study adds to the evidence that odds of successfully tapering opioids may be significantly impacted by patients' mental health diagnosis and opioid dose.
较高的每日阿片类药物剂量以及苯二氮䓬类药物的联合处方与过量风险相关。本研究针对家庭医学实践中与患者心理健康诊断、苯二氮䓬类药物处方、吗啡毫克当量阿片类药物剂量和患者人口统计学特征相关的处方模式进行了描述。
2018 年和 2019 年对接受慢性阿片类药物治疗的患者进行了研究。从电子健康记录中提取心理健康诊断、阿片类药物剂量、苯二氮䓬类药物处方和人口统计学特征数据。比较了两年的数据,并使用逻辑回归来确定哪些患者特征与减少阿片类药物剂量的可能性相关。
2018 年共有 387 名患者被开具慢性阿片类药物处方,2019 年为 231 名。2018 年,49.9%的服用慢性阿片类药物的患者有心理健康诊断。在 2019 年,这一比例上升到了 92.2%。2019 年,在最初的 387 名患者中,仍有 205 名患者在该实践中,但未被开具慢性阿片类药物处方。在所研究的因素中,精神科诊断和较高的阿片类药物剂量与显著降低剂量减少的可能性相关。
随着实践减少或停止开具阿片类药物,或实施减少苯二氮䓬类药物等减少伤害的方法,了解患者特征及其与减少阿片类药物的关系非常重要。本研究增加了证据表明,成功减少阿片类药物的可能性可能会受到患者心理健康诊断和阿片类药物剂量的显著影响。